about
Structural and functional role of threonine 112 in a superantigen Staphylococcus aureus enterotoxin BHigh throughput immuno-screening of cDNA expression libraries produced by in vitro recombination; exploring the Plasmodium falciparum proteome.Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses.A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune responseLevels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved Plasmodium falciparum erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodesRepeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malariaAbnormal proliferation and spontaneous differentiation of myoblasts from a symptomatic female carrier of X-linked Emery-Dreifuss muscular dystrophyExposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malaria.Screening trematodes for novel intervention targets: a proteomic and immunological comparison of Schistosoma haematobium, Schistosoma bovis and Echinostoma caproni.Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development.α2-Macroglobulin Can Crosslink Multiple Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1) Molecules and May Facilitate Adhesion of Parasitized Erythrocytes.Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malariaAntibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areasDiversity covering AMA1-MSP119 fusion proteins as malaria vaccines.Seroepidemiology of Plasmodium species infections in Zimbabwean population.Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum.Immunological consequences of antihelminthic treatment in preschool children exposed to urogenital schistosome infection.Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila.Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria.Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria.High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen.Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso.Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response.Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships.Is Fc gamma receptor IIA (FcγRIIA) polymorphism associated with clinical malaria and Plasmodium falciparum specific antibody levels in children from Burkina Faso?Differential antibody responses to Plasmodium falciparum merozoite proteins in Malawian children with severe malaria.FcγRIIa polymorphism and anti-malaria-specific IgG and IgG subclass responses in populations differing in susceptibility to malaria in Burkina Faso.Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria.Influenza virosomes: a flu jab for malaria?Towards validated assays for key immunological outcomes in malaria vaccine development.Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure.Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1-4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies.Merozoite surface protein 3.3C-specific antibodies block the intraerythrocytic development of Plasmodium falciparum and induce parasite apoptosisInfrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas
P50
Q27636147-CF6B34B6-E057-4F8F-BB28-5F46C5BEC6C1Q31034690-0B16E584-83FB-46D2-BCB0-91069C0341D8Q33385010-E3FCF80A-1513-43F4-AF30-D876CE72CDF4Q34071439-DD6CA2D8-A677-4765-96B0-44BE244137EEQ34601747-944E939E-1D83-4477-ADFC-A8FE062E8BD9Q34855814-98711119-7D29-406A-8311-936946ECBFEFQ35049479-78D3026C-7C14-474C-A4D5-525C9143AAB1Q35228686-3838C854-D431-4D86-8093-C17D2F9A986FQ35230008-FA88C479-A784-4AA0-9935-99CBDFEB1CF8Q35805390-3125DC05-0FA8-4DB9-86CD-F7CB33254D81Q35811289-07DD4AF2-0D18-472D-81BE-DE2759072E27Q36594057-C59C6427-56CD-4342-A045-A0D22D1756B5Q36625461-D5803FF3-7C30-4B81-9D43-9B41A5DD0C70Q36826984-16EE25A8-43D1-4E87-A9F6-2B8AC8711F82Q36890504-9D7EC230-5167-4699-AC95-AD345BC95E53Q36898029-542C4F0B-C0E2-4FC3-9A4C-6ED624C3FC72Q36942712-37DDA798-B829-4E5B-91B2-1289857DC501Q37452080-B211B357-9F3C-468E-B628-880AD5E36E86Q37529646-8644F356-2C27-4879-939E-D1B223AD3D28Q37582802-5500235B-5814-4C9A-B573-A947C7C0459CQ39247931-2053C7DB-242C-4B35-8622-9B5581109C8BQ39362550-0CD7E3FB-0A73-4202-A007-AC5CB5F696A5Q39518664-3FF68DA4-2C05-459C-8B2A-717A73CDE84AQ40059998-723CD3C9-603D-492C-B25E-0B87A4B8DDEDQ40979359-4C407327-FDAF-4ADF-BF5D-3CBC1E557823Q41620472-555D3442-CA3E-4C3A-870F-C1683EB4B6F0Q41635798-45519234-C315-4F3F-95DB-43446D430ED7Q43518867-8D59F245-ECE7-4067-A074-CA66E7F9B64EQ43929748-3ECC3F2B-F97C-45C7-B225-185E5EC2C436Q44379418-CD92B28E-2A6E-42EF-A77D-73F6C3863B8CQ47874621-6DAE810C-D1EC-4B1E-8DB2-03F12C804628Q47971724-ACD66233-5CE6-4BDB-9293-C4E32AEE2F74Q48015973-ECC4D664-C6EC-430F-A282-2A9F009185CCQ55292950-2B2C3960-BCE1-467D-BF8C-5B806F5A23DFQ59291642-CA5BBC83-C29D-4E17-B54F-85AE44485D42Q63634627-1DAB386D-76A5-4548-8EB5-7FCC01E9A66E
P50
description
researcher ORCID ID = 0000-0003-4360-2637
@en
wetenschapper
@nl
name
David Cavanagh
@ast
David Cavanagh
@en
David Cavanagh
@es
David Cavanagh
@nl
type
label
David Cavanagh
@ast
David Cavanagh
@en
David Cavanagh
@es
David Cavanagh
@nl
prefLabel
David Cavanagh
@ast
David Cavanagh
@en
David Cavanagh
@es
David Cavanagh
@nl
P108
P21
P31
P496
0000-0003-4360-2637